Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
ERSPC
About the Trial
The European Randomized Study of Screening for Prostate Cancer randomized men in several European countries to PSA based screening or no screening. The 2009 report in the New England Journal of Medicine found a 20 percent relative reduction in prostate cancer mortality among men aged 55 to 69, but estimated that 1,410 men needed to be screened and 48 additional cancers treated to prevent one death. Published alongside the American PLCO trial, which found no benefit amid heavy screening in its control arm, ERSPC framed the modern debate over overdiagnosis. Longer follow up strengthened the mortality benefit, and guidelines shifted toward shared decision making.
Related Trials
NLST
The National Lung Screening Trial randomized 53,454 heavy smokers to three annual low dose CT scans or chest X rays. CT screening ...
Minnesota Colon Cancer Study
Jack Mandel randomized 46,551 Minnesota adults to annual or biennial fecal occult blood testing or usual care. Annual screening re...
PLCO
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial randomized about 155,000 adults to periodic screening or usual ...
HIP Mammography Trial
Beginning in 1963, the Health Insurance Plan of Greater New York randomized more than 60,000 women aged 40 to 64 to annual mammogr...